SCHEMBL4206169

SCHEMBL4206169

CCCN1CC(c2ccc(NS(=O)(=O)c3ccc(F)c(-c4cocn4)c3)cc2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.40
KIT P10721 2/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
GFER P55789 2/20 0.35
MGAT2 Q10469 2/20 0.35
MGAT1 P26572 1/20 0.35
MLNR O43193 1/20 0.35
ALDH1A1 P00352 4/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
SCN9A Q15858 1/20 0.35
PKM P14618 3/20 0.34
TRIM24 O15164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
THRB P10828 1/20 0.34
MEN1 O00255 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4201243 0.94 HRH3 (0.41) HRH3KITLMNASMN1; SMN2GFER
SCHEMBL4201240 0.94 HRH3 (0.41) HRH3KITLMNASMN1; SMN2GFER
SCHEMBL15048529 0.85 MAPT (0.41) LMNASMN1; SMN2MLNRALDH1A1TP53
SCHEMBL4194643 0.84 HRH3 (0.38) HRH3KITLMNASMN1; SMN2GFER
SCHEMBL4188497 0.81 HRH3 (0.55) HRH3KITLMNASMN1; SMN2GFER
SCHEMBL4199516 0.78 MEN1 (0.48) HRH3LMNASMN1; SMN2GFERALDH1A1
SCHEMBL4192778 0.77 HRH3 (0.41) HRH3LMNASMN1; SMN2GFERTRIM24
SCHEMBL4192775 0.77 HRH3 (0.41) HRH3LMNASMN1; SMN2GFERTRIM24
SCHEMBL4206091 0.75 PGR (0.51) LMNASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL5571596 0.75 HRH3 (0.56) HRH3LMNASMN1; SMN2GFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642642-B2 Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor ABBOTT LABORATORIES (US) 2014-02-04 US disclosed
US-20090306175-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-12-10 US disclosed
EP-2029528-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-03-04 EP disclosed
WO-2007118899-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306175-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR HTR6, HTR1A, HTR5A HRH3 129/4885KIT 668/4885LMNA 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.